1% Topical Pimecrolimus Cream for the Prevention of Rash Associated With the Use of the EGFR Antagonist, Cetuximab
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Pimecrolimus (Primary)
- Indications Exanthema
- Focus Therapeutic Use
- 24 Jan 2017 Status changed from recruiting to discontinued as Interim analysis shows no efficacy.
- 06 Aug 2014 New trial record
- 30 May 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.